Lisinopril: Nursing Drug Guide, Angioedema & Hyperkalemia
Zestril and Prinivil lower blood pressure and support heart failure outcomes, but nurses must guard against angioedema (higher reported incidence in Black patients per labeling), hyperkalemia when potassium supplements or salt substitutes overlap, first-dose hypotension with diuretics, and acute renal injury with NSAIDs or volume depletion—and discontinue immediately when pregnancy is detected.
The Zestril boxed warning states that when pregnancy is detected, lisinopril should be discontinued as soon as possible because drugs acting on the renin–angiotensin system can injure or cause death of the developing fetus. Separately, angioedema of the face, lips, tongue, glottis, or larynx—including fatal cases—has occurred with ACE inhibitors at any time during treatment, with a higher rate in Black than non-Black patients; discontinue immediately and escalate airway care when breathing is threatened. Serum potassium and renal function need periodic surveillance because RAS blockade predisposes to hyperkalemia and acute renal failure, particularly with dehydration, NSAIDs such as ibuprofen, potassium supplements, potassium-sparing diuretics such as spironolactone, or dual RAS inhibition with agents like losartan.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every lisinopril dose, reconcile pregnancy status, airway-threatening swelling, and whether a new diuretic or NSAID could trigger symptomatic hypotension or a creatinine/potassium jump—Zestril labeling emphasizes supervised first doses when diuretics cannot be stopped.
Most common brand names
Lisinopril is the generic name for this angiotensin-converting enzyme inhibitor. Common U.S. brands include Zestril and Prinivil; an oral solution is marketed as Qbrelis. Fixed-dose combinations with thiazide-type diuretics (for example lisinopril–HCTZ products) are widely used—trace both active ingredients through medication reconciliation rather than trusting look-alike bottle labels.
Why we give it — Indications
Zestril prescribing information approves lisinopril for hypertension in adults and pediatric patients ≥6 years, as adjunct therapy for systolic heart failure, and to reduce mortality in hemodynamically stable adults within 24 hours of acute myocardial infarction (with standard MI therapies). Nurses on medical–surgical units most often administer the once-daily antihypertensive tablet; cardiology teams manage heart-failure and post-MI pathways per heart failure protocols.
| Use | Detail |
|---|---|
| Hypertension | Lowers blood pressure; may combine with thiazide-type diuretics when monotherapy is insufficient. |
| Heart failure | Reduces signs and symptoms of systolic heart failure when added to diuretics and (usually) digitalis per labeling trials. |
| Acute MI (stable) | GISSI-3 data cited in labeling showed lower six-week mortality versus no lisinopril in hemodynamically stable patients within 24 hours of MI onset. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Lisinopril is an oral active ACE inhibitor (not a prodrug) that suppresses angiotensin II formation and aldosterone secretion, producing vasodilation with modest serum potassium rises (hypertensive monotherapy trials in labeling report mean increases ≈0.1 mEq/L over 24 weeks, with about 15% of patients rising >0.5 mEq/L). ACE also degrades bradykinin; whether elevated bradykinin contributes both to blood pressure lowering and to nuisance dry cough is discussed in labeling and overlaps mechanistically with angioedema vigilance pathways.
Dosing overview
Doses below reflect the reviewed Zestril label; titrate strictly to clinician orders and to blood pressure plus renal-electrolyte response. Estimated GFR informs starting dose selections described in prescribing information.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Absorption / onset | ≈25% mean oral absorption (wide interpatient variability); antihypertensive effect begins within about 1 h; peak BP reduction by ~6 h | First-dose hypotension risk peaks when diuretics continue—align orthostatic vitals with MAR timing |
| Peak / half-life | Peak serum lisinopril ~7 h after dose; effective half-life ~12 h with once-daily dosing; food does not alter bioavailability | Once-daily scheduling is standard; do not crush/split without pharmacy direction |
| Elimination | Excreted unchanged in urine; accumulation when GFR <30 mL/min; dialyzable | Renal impairment and dialysis timing affect drug levels—coordinate pharmacy when creatinine rises |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Identify pregnancy possibilities in patients of reproductive potential and verify contraceptive or testing plans with prescribing teams
- Review baseline and recent renal function trajectory—especially when starting therapy, escalating dose, restarting after illness, or adding nephrotoxic or hyperkalemia-provoking drugs
- Screen for hypersensitivity or prior ACE inhibitor angioedema per contraindications language
- Confirm interacting agents: NSAIDs, potassium supplements, potassium-sparing diuretics (for example spironolactone), dual RAS-blocking regimens (losartan or ARB combos), neprilysin inhibitors, lithium, mTOR inhibitors, intensified antidiabetic therapy predisposing hypoglycemia
Contraindications (FDA label summary)
- Hypersensitivity to lisinopril or another ACE inhibitor
- History of angioedema including hereditary or idiopathic angioedema
- Combination with neprilysin inhibitor (example sacubitril)—do not start lisinopril within 36 hours of switching from sacubitril/valsartan and vice versa
- Concurrent aliskiren with ACE inhibitors in patients who have diabetes
Important interactions
| Drug / scenario | Effect | Nursing action |
|---|---|---|
| furosemide, thiazide diuretics | Excessive blood pressure drops—especially shortly after initiating or escalating diuretics | Take orthostatic vitals closely first two weeks; escalate symptomatic hypotension or oliguria |
| Potassium-retaining therapies | Combined aldosterone suppression plus spironolactone-type agents or supplementation elevates hyperkalemia incidence | Ensure scheduled BMP follow-up; hold scheduled dose when clinically ordered for critical lab abnormalities pending prescriber contact |
| ibuprofen / COX-2 inhibitors | Reduced antihypertensive effect plus worsened renal impairment risk | Educate OTC avoidance without prescriber review; monitor serum creatinine and blood pressure when short courses are unavoidable |
| Dual RAS inhibition | Higher renal dysfunction, hypotension, and potassium disturbances | Scrutinize inpatient lists for simultaneous ACE, ARB, or direct renin blocker combinations; involve pharmacy early |
On a small screen, swipe or scroll sideways to see the full table.
Administration
- Zestril tablets: 2.5, 5, 10, 20, 30, and 40 mg (imprinted ZESTRIL strengths); swallow intact unless pharmacy directs otherwise
- May be taken with or without food per labeling
- Qbrelis 1 mg/mL oral solution exists for patients who cannot swallow tablets—administer only pharmacy-prepared product per label
- Lisinopril is oral only on typical med-surg units—do not substitute IV ACE inhibitor formulations on the MAR
Expected therapeutic response
- Blood pressure declines within hours of dosing with peak effect around six hours while once-daily dosing maintains 24-hour control per labeling
- Combination with thiazide diuretics may blunt concurrent hypokalemia versus diuretics alone owing to tempered aldosterone signals
- Patients with heart failure should articulate improved exercise tolerance when hypotension-mediated symptoms are absent
Red flags — Stop and act
- Progressive airway-compromising lip swelling, tongue fullness, muffled speech, inspiratory difficulty—assume ACE inhibitor angioedema requiring immediate pathway activation
- Serum potassium climbing trend even before critical numeric threshold—coordinate repeat testing and cessation of potassium introductions
- New oliguria, dizziness, syncope, or collapsing perfusion pressures after initiating therapy or restarting post-acute illness
- Creatinine elevations suggesting acute kidney injury attributable to RAS suppression, volume depletion, or renovascular physiology
- Life-threatening anaphylactoid reactions during high-flux dialysis or hymenoptera desensitization described in prescribing information—stop procedure per protocol and activate resuscitation resources
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| dizziness, headache, cough | Hypertension trials: headache +3.8%, dizziness +3.5%, cough +2.5% versus placebo (events ≥2% greater on lisinopril); HF trials: hypotension +3.8%, chest pain +2.1% | Teach positional caution after first doses; distinguish dry cough from angioedema; hold and escalate symptomatic hypotension |
| Hyperkalemia | Serum K+ >5.7 mEq/L in 2.2% (HTN) and 4.8% (HF) per labeling; higher with potassium-raising drugs | Trend serum potassium; hold and notify when clinically significant per protocol |
| Intestinal angioedema | Abdominal pain with or without nausea/vomiting; may occur without prior facial swelling | Stop ACE inhibitor; notify prescriber; do not dismiss as benign GI upset |
On a small screen, swipe or scroll sideways to see the full table.
Overdose management
Zestril overdosage data in labeling describe animal studies at very high doses. In humans, the most likely manifestation is hypotension; there is no specific reversal agent cited.
Recommended supportive therapies (label)
- Intravenous normal saline infusion for hypotension
- Lisinopril may be removed by hemodialysis
- Supportive perfusion, airway, and electrolyte monitoring per institutional toxicology protocol
- Consult local poison control / toxicology services per facility protocol when ingestion amount or intent is uncertain
Consult local poisoning or toxicology services per institutional policy when intentional overdose or uncertain ingestion volume is reported—even though labeling describes no reversal agent analogous to opioid or acetaminophen pathways.
Look-alike / sound-alike and error prevention
- Zestril / Prinivil versus lisinopril / benazepril / quinapril: ACE inhibitor names and tablet colors vary by manufacturer—barcode every dose
- Lisinopril versus lisinopril–HCTZ combination: confirm whether order references monotherapy versus fixed combination inadvertently duplicated elsewhere
- Strength jumps: 2.5, 5, 10, 20, 30, and 40 mg ZESTRIL-imprinted tablets sit adjacent in ADCs—witness high-risk strengths
- Qbrelis oral solution versus tablets: verify mg versus mL on the MAR; pharmacy should prepare measurable doses
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Swallow intact | Standard Zestril tablets are intended orally intact; Qbrelis solution is pharmacy-specific—not ad hoc crushed tablets unless pharmacy validates. |
| Meal pairing | Food does not materially change exposure—steady daily timing assists vitals and symptom tracking. |
| Orthostatics | Volume-depleted patients merit lying-standing blood pressure during initial therapy weeks per labeling hypotension warnings. |
| Salt substitutes | Potassium-containing substitutes can precipitate hyperkalemia on ACE inhibitors—teach patients to read labels and ask before buying. |
| Airway readiness | Because angioedema may involve laryngeal structures rapidly, confirm emergency airway equipment availability when initiating new RAS inhibitor courses in higher-risk patients. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pregnancy | Zestril labeling links second- and third-trimester fetal injury to renin-angiotensin inhibition (renal hypoperfusion, oligohydramnios-related complications, neonatal renal dysfunction). Nursing priority is cessation as soon as pregnancy is recognized. |
| Renal artery stenosis / volume depletion | Patients whose renal perfusion depends on angiotensin II may develop abrupt creatinine rises or oliguria when ACE inhibition starts—coordinate hold rules with nephrology or cardiology. |
| Pediatrics | Established ages 6–16 years for hypertension when GFR >30 mL/min/1.73 m²; starting dose 0.07 mg/kg (up to 5 mg) once daily per labeling. Not recommended <6 years or GFR <30. |
| Black ancestry monotherapy caveat | Labeling notes smaller average antihypertensive response with ACE monotherapy in Black patients and higher angioedema incidence—prioritize airway teaching regardless of BP response. |
| Lactation | Labeling advises not to breastfeed during lisinopril therapy. LactMed cites very low milk levels (RID ~0.06%) with no serious infant effects in small reports—individualized prescriber discussion when breastfeeding cannot be avoided. |
| type 2 diabetes | Labeling warns increased hypoglycemia risk when antidiabetic medicines overlap—monitor glucose especially during the first month of combined use. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure, heart rate, and hydration status after initiation, dose increases, and restarts following intercurrent illness
- serum creatinine and eGFR trends with electrolytes on the basic metabolic panel, including potassium
- Distinguish nuisance dry cough from progressive inspiratory distress, voice change, or facial swelling that may signal airway angioedema
- Blood glucose when antidiabetic therapy runs concurrently—labeling notes increased hypoglycemia risk with antidiabetic medicines
Document
- Dose, route, time, indication, blood pressure, orthostatic symptoms, OTC NSAID use, and potassium supplements or salt substitutes
- Patient education on pregnancy avoidance, angioedema warning signs, dehydration risk, and hypoglycemia vigilance when diabetes medicines overlap
- Prescriber/pharmacist notifications, hold decisions, rapid response or airway interventions, and repeat lab trends
Patient teaching
- Discuss pregnancy planning—stop lisinopril as soon as pregnancy is suspected or confirmed per the boxed warning
- Teach that facial swelling, lip or tongue swelling, noisy breathing, or swallowing difficulty means stop the drug and seek emergency care immediately—do not take another dose
- Do not start potassium supplements or potassium-containing salt substitutes without prescriber approval
- Report light-headedness, especially when standing; vomiting, diarrhea, heat exposure, and dehydration increase hypotension risk during early therapy
- Patients with diabetes should monitor glucose more closely when ACE inhibitors are added
- Check with the care team before starting OTC NSAIDs such as ibuprofen—combined use can worsen renal function and blunt blood pressure control
The Hold Rule
Hold (clinician-aligned) dosing and escalate when:
- Pregnancy confirmed or suspected—discontinue immediately and notify the prescriber for obstetric follow-up
- Angioedema or any airway-threatening swelling of the face, lips, tongue, or throat—hold and escalate per emergency protocol
- Hyperkalemia, oliguria, or rising creatinine after dehydration, NSAID use, or dual RAS-blocking therapy—hold and clarify with prescriber/pharmacist
- Symptomatic hypotension, syncope, or shock until volume status and orders are reviewed
- Prohibited combinations on the MAR (dual RAS blockade, aliskiren with ACE inhibitor in diabetes, neprilysin inhibitor within 36-hour switch window, or suspected lithium toxicity)
Clinical practice integration and workflow
1. Stewardship checkpoints
- Barcode verify lisinopril/Zestril strength before every administration pass
- Pair blood pressure captures with electrolyte renal panels after therapy starts or adjunct drugs change
- Screen admission medication lists for OTC renal stressors undocumented preadmission NSAID aspirin stacks
2. High-alert designation
Not universally classified institutional high-alertTreat lisinopril with proportional vigilance analogous high-stakes cardiometabolic meds because fetal catastrophe airway angioedema and renal failure potentials exceed ordinary oral antihypertensive error tolerance.
3. Hold and question cues
- New tongue thickness lip asymmetry vocal changes—assume ACE inhibitor airway emergency until clarified
- Creatinine jump ≥30% clinician-defined institution thresholds after RAS initiation mandates hold clarification per policy
- Patient purchased OTC anti-inflammatory pills without informing team—coordinate pause teaching prescriber review
Teach-back prompts
- “Which swelling symptoms mean you skip further doses tonight?” (Patient should articulate face lip tongue airway difficulty emergency activation.)
- “Why should potassium salt substitutes worry your heart team?” (Patient references hyperkalemia coupling ACE inhibition.)
Pharmacist collaboration: Neprilysin sacubitril/valsartan transition windows NSAID unavoidable courses lithium dosing potassium binder coordination breastmilk counselling.
Prescriber / specialist: Resistant hypertension dialysis membrane planning angioedema recurrence pregnancy confirmation hyperkalemia refractory escalating renal insults unexplained hepatic enzyme cholestasis alerts.
🧠 Quick mental checklist
- Airway—is there progressing lip tongue voice change after today’s lisinopril doses?
- Renal trajectory—Scr potassium sodium pairing volume status fair?
- Pregnancy possibility documentation contraception counseling complete?
- New NSAID potassium supplementation salt substitutes reviewed?
- If hypotensive after suspected overdose—is volume resuscitation pathway prepared though no antidote?
Lisinopril NCLEX practice questions
Practice NCLEX-style clinical judgment practice for lisinopril: use the case tabs (MAR, Labs, I&O, Nursing notes) to judge hyperkalemia with salt substitutes, angioedema escalation, SATA cue recognition, potassium/creatinine trend SATA, urgency matrix sorting, diuretic first-dose MCQ, and overdose cloze focused on hypotension and hemodialysis—not a labeled antidote.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Lisinopril 20 mg PO daily — due 0800 (home dose continued on admission)
- Hydrochlorothiazide 25 mg PO daily — given 0700
- Potassium chloride 20 mEq PO daily — new order yesterday (pharmacy verified)
- BMP this morning: potassium 6.1 mEq/L (repeat pending); creatinine 1.9 mg/dL (admission 1.3)
- ECG: peaked T waves — cardiology notified
- Sodium 136 mEq/L; BUN 38 mg/dL
- Urine output 420 mL over past 8 h (expected ~640 mL for intake)
- Oral intake modest; patient reports muscle cramping in calves overnight
- Weight stable; no edema at 0730 assessment
- Patient started using spouse’s “heart-healthy” potassium-based salt substitute at meals two days ago—was not on home med list at admission
- No lip or tongue swelling at 0730; denies shortness of breath
- Reports generalized weakness; BP sitting 118/70 mm Hg, HR 88
Answer key & rationale
Frequently asked questions
What should I check before giving lisinopril?
Review the latest basic metabolic panel (especially potassium and creatinine), confirm blood pressure and orthostatic symptoms, verify pregnancy status in patients of childbearing potential, scan the MAR for potassium supplements or potassium-containing salt substitutes, potassium-sparing diuretics, NSAIDs, lithium, dual renin-angiotensin system blockade, and neprilysin inhibitors, and match tablet strength (2.5–40 mg) or pharmacy-prepared suspension to the order.
When should nurses hold lisinopril?
Hold and contact the prescriber or pharmacist when potassium exceeds protocol limits or ECG changes suggest hyperkalemia, creatinine rises sharply or acute renal failure is suspected, symptomatic hypotension or oliguria occurs—especially with diuretics or volume depletion—pregnancy is confirmed or suspected, angioedema or airway-threatening swelling develops, or known ACE inhibitor hypersensitivity exists.
Why is hyperkalemia a top lisinopril safety concern?
ACE inhibition reduces aldosterone-driven potassium excretion. Zestril labeling reports hyperkalemia (serum potassium greater than 5.7 mEq/L) in 2.2% of hypertensive and 4.8% of heart-failure patients, with higher rates when potassium-sparing diuretics, supplements, or salt substitutes overlap.
What happens if pregnancy is detected on lisinopril?
Discontinue lisinopril as soon as possible per the boxed warning. Drugs acting on the renin-angiotensin system can injure or kill the developing fetus through reduced fetal renal function, oligohydramnios-related complications, and neonatal renal failure.
Is there an antidote for lisinopril overdose?
No specific antidote is listed in the reviewed prescribing information. Overdosage most likely causes hypotension treated with intravenous normal saline; lisinopril may be removed by hemodialysis. Consult local poison control or medical toxicology services per facility guidance when ingestion is intentional or dose is uncertain.
Can patients breastfeed while taking lisinopril?
Zestril labeling advises women not to breastfeed during treatment because of potential for severe adverse reactions in the infant. LactMed reports very low milk levels (relative infant dose about 0.06%) with no serious infant effects reported in small studies—individualized prescriber discussion remains required when breastfeeding cannot be avoided.
References
-
U.S. National Library of Medicine. Zestril (lisinopril) tablet — prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8
-
Drugs and Lactation Database (LactMed). Lisinopril. Bethesda (MD): National Institute of Child Health and Human Development; updated 2025.https://www.ncbi.nlm.nih.gov/books/NBK501006/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and pharmacist review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.